Tolerogenic strategies to halt or prevent type I diabetes

Nature Immunology

Volumn 2, Issue 9, 2001, Pages 810-815

  Cooke, Anne ^a   Phillips, Jenny M ^a   Parish, Nicole M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; B7 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; CYTOKINE; CYTOKINE ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; OKT 3; OKT 4; OKT 8; PHOSPHATASE; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; CELL REGENERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIGENS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MODELS, IMMUNOLOGICAL; MYCOBACTERIUM INFECTIONS; PANCREATITIS; SCHISTOSOMIASIS MANSONI; SELF TOLERANCE; T-LYMPHOCYTES;

EID: 0035554687     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni0901-810     Document Type: Review

References (65)

1. Thymic expression of autoantigens correlates with resistance to autoimmune disease
2. Peripheral-antigen-expressing cells in thymic medulla: Factors in self-tolerance and autoimmunity
3. An investigation of the nature of induced suppression to experimental autoimmune thyroiditis
4. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
5. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant
6. Antigen-driven tissue-specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse
7. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity
8. Regulation of encephalitogenic T cells with recombinant TCR ligands
9. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
10. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity
11. The spontaneously diabetic Wistar rat (the "BB" rat). Studies prior to and during development of the overt syndrome
12. Genetics of type I diabetes
13. Characterization of pancreatic islet cell infiltrates in NOD mice: Effect of cell transfer and transgene expression
14. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: A longitudinal study
15. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases
16. Interferon-γ enhances the expression of the major histocompatibility class I antigens on mouse pancreatic β cells
17. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process
18. Islet cytotoxicity of interleukin I. Influence of culture conditions and islet donor characteristics
19. A 1-hour pulse with IL-I β induces formation of nitric oxide and inhibits insulin secretion by rat islets of Langerhans: Evidence for a tyrosine kinase signaling mechanism
20. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration
21. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent
22. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice
23. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
24. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy
25. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes
26. + T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway
27. + T cells to cause immunopathology
28. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum
29. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to β cells in NOD mice
30. + T cells in the initiation of insulin-dependent diabetes mellitus
31. Thymus-dependent monoclonal antibody-induced protection from transferred diabetes
32. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice
33. In vivo prevention of thyroid and pancreatic autoimmunity in the BB rat by anti-body to class II major histocompatibility complex gene products
34. Anti-α/β T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice
35. Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD/Shi/Kbe mice by anti-MHC class I Kd monoclonal antibody
36. Prevention of autoimmune but not allogeneic destruction of grafted islets by different therapeutic strategies
37. Neonatal activation of CD28 signaling overcomes T cell energy and prevents autoimmune diabetes by an IL-4-dependent mechanism
38. Prolonged islet graft survival in NOD mice by blockade of the CD40- CD154 pathway of T-cell costimulation
39. Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic β cells
40. + T cells
41. "Infectious" transplantation tolerance
42. Infectious tolerance
43. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection
44. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
45. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids
46. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γl (Ala-Ala) in the treatment of acute renal allograft rejection
47. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection
48. Anti-TNF-α therapy of rheumatoid arthritis: What have we learned?
49. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination
50. Mechanisms of Mycobacterium avium-induced resistance against insulin-dependent diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice: Role of Fas and ThI cells
51. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein
52. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: Modulation of spontaneous 60-kDa heat shock protein autoimmunity
53. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex
54. Endocytosed heat shock protein 60s use TLR2 and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells
55. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice
56. The internal secretion of the pancreas
57. Islet transplantation in seven patients with type I diabetes mellitus using a gluco-corticoid-free immunosuppressive regimen
58. From stem cells to β cells: New strategies in cell therapy of diabetes mellitus
59. Islets of Langerhans: The puzzle of intraislet interactions and their relevance to diabetes
60. Epithelial cell proliferation and islet neogenesis in IFN-γ transgenic mice
61. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells
62. In vitro cultivation of human islets from expanded ductal tissue
63. α-Cell neogenesis in an animal model of IDDM
64. Insulin-promoter-factor I is required for pancreas development in mice